• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

克服药物庇护所。

Overcoming pharmacologic sanctuaries.

机构信息

Antiviral Pharmacology Laboratory, University of Nebraska Medical Center, College of Pharmacy, Omaha, NE 68198, USA.

出版信息

Curr Opin HIV AIDS. 2013 May;8(3):190-5. doi: 10.1097/COH.0b013e32835fc68a.

DOI:10.1097/COH.0b013e32835fc68a
PMID:23454865
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3677586/
Abstract

PURPOSE OF REVIEW

Current antiretroviral treatment regimens represent significant improvements in the management of HIV-1 infection; however, these regimens have not achieved a functional or sterilizing cure. One barrier to achieving a cure may be suboptimal antiretroviral concentrations in sanctuary sites throughout the body, including the central nervous system, gut-associated lymphoid tissue, lymph nodes, and tissue macrophages. This review will focus on the problems associated with achieving effective concentrations in these restricted sanctuary sites, and potential strategies to overcome these barriers.

RECENT FINDINGS

Sufficient data exist to conclude that antiretroviral drug distribution is not uniform throughout the body. Low tissue/reservoir concentrations may be associated with viral replication. Multiple means to increase drug concentrations in sanctuary sites are being investigated, including modification of currently utilized drugs, blockade of transporters and enzymes that affect drug metabolism and pharmacokinetics, and local drug administration. Accumulating data suggest these methods increase antiretroviral concentrations in reservoirs of viral replication. No method has yet resulted in the complete clearance of HIV.

SUMMARY

New strategies for increasing antiretroviral concentrations in predominant sites of viral replication may provide more effective means for elimination of viral sanctuaries. Additional research is necessary to optimize antiretroviral tissue distribution in order to inhibit virus replication fully, and avoid resistance and replenishment of viral reservoirs that may persist in the face of antiretroviral therapy.

摘要

目的综述

目前的抗逆转录病毒治疗方案代表了 HIV-1 感染管理的重大进展;然而,这些方案并未实现功能性或杀菌性治愈。实现治愈的一个障碍可能是全身避难所部位(包括中枢神经系统、肠道相关淋巴组织、淋巴结和组织巨噬细胞)的抗逆转录病毒浓度不理想。这篇综述将重点讨论在这些受限的避难所部位实现有效浓度的问题,以及克服这些障碍的潜在策略。

最近的发现

有足够的数据得出结论,抗逆转录病毒药物在全身的分布并不均匀。组织/储存浓度低可能与病毒复制有关。正在研究多种增加避难所部位药物浓度的方法,包括对现有药物进行修饰、阻断影响药物代谢和药代动力学的转运体和酶,以及局部给药。越来越多的数据表明,这些方法增加了病毒复制的储库中的抗逆转录病毒浓度。目前还没有一种方法能完全清除 HIV。

总结

增加主要病毒复制部位抗逆转录病毒浓度的新策略可能为消除病毒避难所提供更有效的方法。为了完全抑制病毒复制,避免耐药性和可能在抗逆转录病毒治疗下持续存在的病毒储存库的补充,有必要进一步研究优化抗逆转录病毒的组织分布。

相似文献

1
Overcoming pharmacologic sanctuaries.克服药物庇护所。
Curr Opin HIV AIDS. 2013 May;8(3):190-5. doi: 10.1097/COH.0b013e32835fc68a.
2
The Importance of Tissue Sanctuaries and Cellular Reservoirs of HIV-1.HIV-1 的组织避难所和细胞储库的重要性。
Curr HIV Res. 2022 Aug 12;20(2):102-110. doi: 10.2174/1570162X20666211227161237.
3
Lopinavir/ritonavir: a review of its use in the management of HIV infection.洛匹那韦/利托那韦:其在HIV感染管理中的应用综述
Drugs. 2003;63(8):769-802. doi: 10.2165/00003495-200363080-00004.
4
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.人类免疫缺陷病毒基因耐药性检测对治疗效果的影响研究。
Verh K Acad Geneeskd Belg. 2001;63(5):447-73.
5
Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.人类免疫缺陷病毒感染患者储存库和庇护所部位蛋白酶抑制剂浓度与病毒载量之间的差异。
Antimicrob Agents Chemother. 2003 Jan;47(1):238-43. doi: 10.1128/AAC.47.1.238-243.2003.
6
HIV-1 Sanctuary Sites-the Role of Membrane-Associated Drug Transporters and Drug Metabolic Enzymes.HIV-1 避难所部位——膜相关药物转运体和药物代谢酶的作用。
AAPS J. 2020 Sep 1;22(5):118. doi: 10.1208/s12248-020-00498-1.
7
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.HIV-1储存库:在抗病毒免疫反应和抗逆转录病毒疗法存在的情况下病毒持续存在的机制
Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665.
8
The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.遗传药理学在 HIV 治疗中的双重作用:调控抗逆转录病毒药物耐药性和药物处置的突变和多态性。
Pharmacol Rev. 2012 Jul;64(3):803-33. doi: 10.1124/pr.111.005553.
9
Antiretroviral drug concentrations in semen of HIV-1 infected men.HIV-1感染男性精液中的抗逆转录病毒药物浓度。
Sex Transm Infect. 2001 Feb;77(1):4-11. doi: 10.1136/sti.77.1.4.
10
The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.富马酸替诺福韦二吡呋酯和替诺福韦艾拉酚胺在感染 HIV 人群中的淋巴组织药代动力学。
Clin Pharmacol Ther. 2020 Nov;108(5):971-975. doi: 10.1002/cpt.1883. Epub 2020 Jun 11.

引用本文的文献

1
Molecular characterization of HIV-1 near-full-length proviral quasispecies in monocytes from patients across different virological responses.不同病毒学反应患者单核细胞中HIV-1近全长前病毒准种的分子特征分析
Front Microbiol. 2025 Aug 21;16:1647986. doi: 10.3389/fmicb.2025.1647986. eCollection 2025.
2
Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination.通过免疫调节和疫苗接种增强广泛中和抗体对 HIV 的抑制作用。
Front Immunol. 2024 Nov 7;15:1478703. doi: 10.3389/fimmu.2024.1478703. eCollection 2024.
3
Improved Automated Radiosynthesis of [F]Dolutegravir: Toward Clinical Applications.[F]度鲁特韦的改进型自动化放射性合成:迈向临床应用
ACS Omega. 2024 Sep 27;9(40):41732-41741. doi: 10.1021/acsomega.4c05893. eCollection 2024 Oct 8.
4
HIV vaccination: Navigating the path to a transformative breakthrough-A review of current evidence.HIV疫苗接种:探寻变革性突破之路——当前证据综述
Health Sci Rep. 2024 Sep 23;7(9):e70089. doi: 10.1002/hsr2.70089. eCollection 2024 Sep.
5
A macrophage-cell model of HIV latency reveals the unusual importance of the bromodomain axis.HIV 潜伏期的巨噬细胞模型揭示了溴结构域轴的不寻常重要性。
Virol J. 2024 Apr 5;21(1):80. doi: 10.1186/s12985-024-02343-9.
6
Dolutegravir quantification in wistar rat tissues following chronic administration.慢性给药后Wistar大鼠组织中多替拉韦的定量分析。
Heliyon. 2023 Nov 18;9(12):e22541. doi: 10.1016/j.heliyon.2023.e22541. eCollection 2023 Dec.
7
Mathematical Models of HIV-1 Dynamics, Transcription, and Latency.HIV-1 动力学、转录和潜伏的数学模型。
Viruses. 2023 Oct 19;15(10):2119. doi: 10.3390/v15102119.
8
Humanized Mice for Studies of HIV-1 Persistence and Elimination.用于研究HIV-1持续性和清除的人源化小鼠
Pathogens. 2023 Jun 27;12(7):879. doi: 10.3390/pathogens12070879.
9
Circadian-Coupled Genes Expression and Regulation in HIV-Associated Chronic Obstructive Pulmonary Disease (COPD) and Lung Comorbidities.HIV 相关慢性阻塞性肺疾病(COPD)和肺部合并症中的昼夜节律相关基因表达和调控。
Int J Mol Sci. 2023 May 23;24(11):9140. doi: 10.3390/ijms24119140.
10
MAdCAM-1 costimulation in the presence of retinoic acid and TGF-β promotes HIV infection and differentiation of CD4+ T cells into CCR5+ TRM-like cells.维甲酸和 TGF-β存在时,MAdCAM-1 共刺激促进 HIV 感染和 CD4+T 细胞分化为 CCR5+TRM 样细胞。
PLoS Pathog. 2023 Mar 10;19(3):e1011209. doi: 10.1371/journal.ppat.1011209. eCollection 2023 Mar.

本文引用的文献

1
Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.考比司他(GS-9350):一种强效且选择性的人CYP3A抑制剂,作为新型药物增强剂。
ACS Med Chem Lett. 2010 May 17;1(5):209-13. doi: 10.1021/ml1000257. eCollection 2010 Aug 12.
2
Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro.科维西司他提高了包括 HIV 蛋白酶抑制剂和 GS-7340 在内的转运底物在肠道的吸收,这是在体外研究中发现的。
Antimicrob Agents Chemother. 2012 Oct;56(10):5409-13. doi: 10.1128/AAC.01089-12. Epub 2012 Jul 30.
3
Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.纳米剂型抗逆转录病毒药物组合在感染 HIV-1 的人外周血淋巴细胞重建小鼠体内的药效学和抗逆转录病毒活性。
J Infect Dis. 2012 Nov 15;206(10):1577-88. doi: 10.1093/infdis/jis395. Epub 2012 Jul 17.
4
Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles.CD4 靶向脂质纳米粒中加入茚地那韦增强抗 HIV 疗效。
J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):417-24. doi: 10.1097/QAI.0b013e3182653c1f.
5
Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340.口服核苷酸前药 GS-7340 后有效淋巴样细胞和组织加载的机制。
Mol Pharm. 2013 Feb 4;10(2):459-66. doi: 10.1021/mp3002045. Epub 2012 Jul 12.
6
Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.单核吞噬细胞细胞间串扰促进靶向细胞的纳米抗逆转录病毒药物向人脑内皮细胞的传递。
Int J Nanomedicine. 2012;7:2373-88. doi: 10.2147/IJN.S29454. Epub 2012 May 8.
7
Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.利托那韦在肠道中增强 HIV 蛋白酶抑制剂的作用:基于 Caco-2 单层和小鼠原位肠灌注的细胞色素 P450 和 P-糖蛋白抑制的相对作用。
Drug Metab Dispos. 2012 Aug;40(8):1473-7. doi: 10.1124/dmd.112.044677. Epub 2012 May 1.
8
Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study.接受含依曲韦林的抗逆转录病毒治疗的 HIV-1 感染妇女的宫颈阴道部位的依曲韦林浓度:DIVA 02 研究。
Antimicrob Agents Chemother. 2012 Jul;56(7):4018-20. doi: 10.1128/AAC.06474-11. Epub 2012 Apr 23.
9
Zidovudine and ursodeoxycholic acid conjugation: design of a new prodrug potentially able to bypass the active efflux transport systems of the central nervous system.齐多夫定和熊去氧胆酸的缀合:一种新前药的设计,可能能够绕过中枢神经系统的主动外排转运系统。
Mol Pharm. 2012 Apr 2;9(4):957-68. doi: 10.1021/mp200565g. Epub 2012 Mar 5.
10
Cytomegalovirus retinitis successfully treated with ganciclovir implant in a patient with blood ganciclovir resistance and ocular ganciclovir sensitivity.在一名对血液中更昔洛韦耐药但眼部对更昔洛韦敏感的患者中,更昔洛韦植入物成功治疗巨细胞病毒性视网膜炎。
Eye (Lond). 2012 May;26(5):759-60. doi: 10.1038/eye.2012.17. Epub 2012 Feb 10.